Regular blood pressure monitoring is essential if both are used together
Food and Drug Administration Primary regulatory Apr 22, 2026 accessed Jul 16, 2026 FDA compounding-risk page whose withdrawn-nomination table includes GHK-Cu for injectable routes
Contrairement a la plupart des peptides modernes, aucun recepteur specifique a haute affinite n'a ete clone et formellement caracterise pour le DSIP, et ce malgre quatre decennies de travaux
Both drugs are being developed by Novo Nordisk, likely reflecting a portfolio strategy: CagriSema as the first-to-market injectable combination, and amycretin as a follow-on oral option for patients who prefer pills
That concern came up directly, and it is a fair question
Journal of Clinical Medicine, 7 (10), 304